Q32 Bio Inc. Share Price & Technical Analysis
QTTB · $5.80 (+5.45%)
Healthcare / Biotechnology
$5.80
+5.45%
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical tr…
Price chart
Seasonality
May has 3 positive and 2 negative years (last 5 years shown)
4% return in May, 0% avg return in past 3 year May month.
73% return in 2026, 7% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 18% | 21% | 45% | -15% | 4% | – | – | – | – | – | – | – | 73% |
| 25 | -12% | -23% | -30% | 0% | 6% | -17% | 47% | -23% | 25% | 40% | -24% | -21% | -33% |
| 24 | 14% | 40% | 2% | 58% | -7% | -29% | 113% | 14% | 3% | 5% | -43% | -87% | 82% |
| 23 | 23% | -2% | -32% | -7% | 1% | -15% | 64% | -12% | -2% | -11% | -48% | 14% | -28% |
| 22 | 1% | -7% | -12% | -45% | -12% | 28% | 10% | 10% | -30% | -9% | 3% | -18% | -82% |
Monthly return % by calendar month · historical pattern, not a forecast
Neutral · Strong · Uptrend
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata. It also develops ADX-096, a C3d mAb CR1 fusion protein for use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition and a range of other indications. The company was founded in 2017 and is based in Waltham, Massachusetts.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$93.94M
P/E ratio
1.99
52W high
$8.04
52W low
$1.34
Volume
6,29,107
Beta
-1.27
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Q32 Bio Inc. share price today?
- Q32 Bio Inc. (QTTB) last traded around $5.80 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does QTTB have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for QTTB. Download the app for real-time alerts.
- How can I analyze Q32 Bio Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.